Setsuro Tech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Apr 25 2021 Read 2 Times Setsuro Tech, a Japanese biotechnology start-up using genome-editing techniques to develop and supply cell and animal models, has signed a non-exclusive license for access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan. “The versatility and programmability of Cas9 has enabled the CRISPR/Cas9 technology to become a revolutionary approach in biological research,” said Eric Rhodes, CEO of Dublin-based ERS Genomics. “We are pleased to support Setsuro Tech with this license agreement so that they are able to continue providing supportive tools and services...

Published: Mar 11, 2021 By Alex Keown Saniona, a rare disease-focused company based in Sweden, received feedback from the U.S. Food and Drug Administration (FDA) on a path forward for its hypothalamic obesity (HO) drug Tesomet. Based on guidance from the regulatory agency, Saniona is planning a Phase IIb study in this indication in the first half of this year. “There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” Rudolf Baumgartner, Chie...

Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models ERS Genomics Limited, which was formed to provide broad access to the foundational